A roundup of biopharma news and updates includes Merck and Eisai’s Keytruda-Lenvima combo hitting the mark in a Phase III study for advanced endometrial cancer.

AstraZeneca, which is jointly developing a Covid-19 vaccine with the University of Oxford, plans to begin clinical trials testing the company’s vaccine in combination with Russia’s Sputnik V vaccine by the end of 2020.

AstraZeneca and Oxford University have more work to do to confirm whether their Covid-19 vaccine can be 90% effective, peer-reviewed data published in The Lancet showed, potentially slowing its eventual rollout in the fight against the pandemic.

A roundup of some of the latest scientific studies on the novel coronavirus includes research on whether a childhood vaccine may help prevent severe Covid-19 and whether cigarette smoke increases cell vulnerability to Covid-19.

Russia’s Sputnik V vaccine is 92% effective at protecting people from Covid-19 according to interim trial results, the country’s sovereign wealth fund said, as Moscow rushes to keep pace with Western drugmakers in the race for a shot.

The world is caught in a perfect storm of rising rates of chronic disease, persistent infectious diseases and public health failures that have fuelled deaths in the Covid-19 pandemic, according to a major global study of human health.

Political polarization and online misinformation are threatening vaccination programs worldwide, with public trust volatile and varying widely between countries, according to a global vaccine confidence study.

Russia’s “Sputnik-V” Covid-19 vaccine produced an antibody response in all participants in early-stage trials, according to results published by The Lancet medical journal.

The University of Oxford suggested that the end of 2020 is possible for the availability of a Covid-19 vaccine candidate being developed with AstraZeneca, but expressed caution about the timeline.

An experimental coronavirus vaccine being developed by AstraZeneca and the University of Oxford was safe and produced an immune response in early-stage clinical trials, data showed, keeping alive the hope AZD1222 could be in use by the end of 2020.